Autigen Announces Collaboration with Boehringer Ingelheim
Innovation 2 Enterprise
APRIL 18, 2022
Collaboration and licensing agreement to advance novel therapies for sensorineural hearing loss (SNHL), where there are currently no approved pharmacological therapies. About 430 million people suffer from moderate to complete hearing loss worldwide, a number expected to rise to about 700 million by 2050. About Autigen.
Let's personalize your content